Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 33.46M P/E - EPS this Y 39.20% Ern Qtrly Grth -
Income -36.8M Forward P/E -1.26 EPS next Y 24.10% 50D Avg Chg -6.00%
Sales 1.02M PEG - EPS past 5Y - 200D Avg Chg -43.00%
Dividend N/A Price/Book 0.64 EPS next 5Y - 52W High Chg -82.00%
Recommedations 2.70 Quick Ratio 1.30 Shares Outstanding 13.37M 52W Low Chg 7.00%
Insider Own 9.94% ROA -16.67% Shares Float 6.05M Beta 1.01
Inst Own 53.66% ROE -101.76% Shares Shorted/Prior 182.85K/203.08K Price 4.06
Gross Margin 30.69% Profit Margin - Avg. Volume 18,909 Target Price 3.75
Oper. Margin -5,445.19% Earnings Date Nov 7 Volume 33,497 Change -1.69%
About OncoCyte Corporation

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Corporation News
11/13/24 OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...
11/12/24 Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
11/06/24 Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
10/16/24 Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
10/08/24 Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
10/04/24 OncoCyte Secures Funding Through Private Share Sale
10/02/24 Oncocyte Signs Leading Transplant Centers in US and Germany
10/02/24 Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
08/20/24 PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
08/12/24 Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
08/08/24 Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
08/01/24 Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
07/11/24 MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode
06/24/24 Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
06/17/24 Oncocyte Appoints Andrea James as Chief Financial Officer
06/05/24 OncoCyte's Innovative Approach: Potential in Precision Diagnostics
06/03/24 Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study
05/30/24 Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
05/15/24 Oncocyte Reports First Quarter 2024 Financial Results
05/13/24 Oncocyte to Announce First Quarter 2024 Financial Results
OCX Chatroom

User Image JohnPDaly Posted - 1 day ago

$LCTX let’s not forget our little brother $OCX during these challenging times.

User Image Liverpool00 Posted - 1 day ago

$OCX will they di another dilute to pay the electric bill. who stuffs themselves with the offerjngs besides the broad men? when us the next teverse split? big bonuses have to be paid year end!!

User Image PenkeTrading Posted - 1 day ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of OncoCyte Corp. Is that bullish or bearish? $OCX #OncoCyte #RsiOversold #NASDAQ

User Image JohnPDaly Posted - 1 week ago

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 $OCX https://finance.yahoo.com/news/oncocyte-reports-commercial-launch-progress-210500274.html

User Image JohnPDaly Posted - 2 weeks ago

$OCX I rode this to $6bucks a share pre-reverse split. Let’s see if they can pull this off.

User Image Mrkeli Posted - 2 weeks ago

$OCX still holding tho, but this board is dead, and i just cant be the only one that is posting here

User Image Mrkeli Posted - 2 weeks ago

$OCX slap that askk boyss

User Image Mrkeli Posted - 2 weeks ago

$OCX nice volume at the start of session, more eyes on it, keep it upp 💥 $TNXP $AMIX $JL $STBX

User Image Liverpool00 Posted - 10/31/24

$OCX shouldnt this hog be below zero?

User Image Mrkeli Posted - 10/31/24

$OCX almost 50 new watchers this week!

User Image Mrkeli Posted - 10/31/24

Good morning all $OCX Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. $VSTE $JL $THAR $MAXN

User Image Mrkeli Posted - 10/30/24

$OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $THAR $JL $TWG $STBX

User Image Amkh9988 Posted - 10/30/24

$OCX sleepy joe

User Image Mrkeli Posted - 10/30/24

Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $THAR $JL $STBX $IBRX

User Image Mimarcano Posted - 10/30/24

$OCX 👀👀

User Image Mrkeli Posted - 10/30/24

guys check low floater $OCX (5 million float) , when this gets attention it can go parabolical, needs volume imo. Insiders bought 3.5 million at 2.95$ and i think this is the bottom $GME

User Image Mrkeli Posted - 10/30/24

guys check low floater $OCX (5 million float) , when this gets attention it can go parabolical, needs volume imo. Insiders bought 3.5 million at 2.95$ and i think this is the bottom $LTBR $LIXT $WGS $LUCY

User Image patbones007 Posted - 10/30/24

$EVOK $VKTX $IBRX $OCX $AMIX

User Image patbones007 Posted - 10/30/24

$LTBR $PFIE $OCX $LIXT $WGS

User Image Mrkeli Posted - 10/30/24

Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $LIXT $WGS $PFIE $LTBR

User Image Mrkeli Posted - 10/30/24

Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $STBX $JL $EVOK $AMIX

User Image Mrkeli Posted - 10/29/24

$OCX starting in 15 minutes, watch here call conference https://me24.sequireevents.com/

User Image Mrkeli Posted - 10/29/24

$OCX Earnings in two weeks, i hope we se some movement before that

User Image Mrkeli Posted - 10/29/24

$JL $STBX $CTNT Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word

User Image Mrkeli Posted - 10/29/24

$JL Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word

User Image Mrkeli Posted - 10/29/24

Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $HRYU $GLUE $AMIX $EVOK

User Image Mrkeli Posted - 10/29/24

Guys check $OCX: Low float 5.5 million 💥 Insiders recetly bought 3.9 million shares at 2.95 Institutional ownership about 55% Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. Earnings in two weeks. Spread the word $HRYU $GLUE $AMIX $EVOK

User Image Mrkeli Posted - 10/28/24

$HRYU Guys check $OCX: Low float 5.5 million Insiders recetly bought 3.9 million shares at 2.95 Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. I think this is bottom.

User Image Mrkeli Posted - 10/28/24

$HRYU Guys check $OCX: Low float 5.5 million Insiders recetly bought 3.9 million shares at 2.95 Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. I think this is bottom.

User Image Mrkeli Posted - 10/28/24

@Paraboljoker check $OCX: Low float 5.5 million Insiders recetly bought 3.9 million shares at 2.95 Partnership with Bio Rad laboratories with mc of 9 billion They have 4 main products which could increase their revenue significantly. I think this is bottom.

Analyst Ratings
Needham Buy Aug 9, 24
Needham Buy May 16, 24
Needham Buy Apr 24, 24
Stephens & Co. Equal-Weight Apr 17, 24
Benchmark Speculative Buy Apr 15, 24
Piper Sandler Neutral Nov 13, 23
Needham Buy Nov 9, 23
Benchmark Speculative Buy Aug 24, 23
Piper Sandler Neutral Aug 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KINGSLEY ALFRED D Director Director Jun 14 Buy 0.2149 30,000 6,447 469,111 06/15/23
PURA VIDA INVESTMENTS, LLC 10% Owner 10% Owner Apr 05 Buy 0.3017 663,000 200,027 8,090,202 04/07/23
BROADWOOD PARTNERS, L.P. 10% Owner 10% Owner Apr 03 Buy 0.15 26,827,638 4,024,146 50,181,335 04/05/23
KINGSLEY ALFRED D Director Director Dec 22 Buy 0.285 25,000 7,125 439,111 12/27/22
Last Andrew J. Director Director Aug 17 Buy 0.87 20,000 17,400 70,170 08/19/22
Arno Andrew Director Director Aug 17 Buy 0.9 15,000 13,500 15,000 08/19/22
KINGSLEY ALFRED D Director Director Aug 15 Buy 0.97 10,000 9,700 414,111 08/17/22
Gutfreund John Peter Director Director Aug 15 Buy 0.93 25,000 23,250 25,000 08/17/22
GRIFFITH MELINDA Director Director Aug 15 Buy 1 10,000 10,000 30,000 08/17/22
Carter Jennifer L. Director Director Aug 15 Buy 0.95 10,500 9,975 30,500 08/17/22
Arno Andrew Director Director Aug 15 Buy 0.95 150,000 142,500 282,049 08/17/22
PURA VIDA INVESTMENTS, LLC 10% Owner 10% Owner Jun 24 Sell 1.04 99,386 103,361 8,479,682 06/28/22
PURA VIDA INVESTMENTS, LLC 10% Owner 10% Owner Apr 14 Buy 1.24 200,000 248,000 8,532,663 06/28/22
Yu Li VP Cntrllr/Prncpl Ac.. VP Cntrllr/Prncpl Acctng Offcr May 18 Option 0 25,000 25,000 05/19/22
Yu Li VP Cntrllr/Prncpl Ac.. VP Cntrllr/Prncpl Acctng Offcr May 18 Sell 1.14 8,128 9,266 16,872 05/19/22
BROADWOOD PARTNERS, L.P. 10% Owner 10% Owner Apr 13 Buy 0.67 6,003,752 4,022,514 23,353,697 04/15/22
Ross Douglas T. Chief Scientific Off.. Chief Scientific Officer Mar 25 Buy 1.40 15,000 21,000 20,317 03/28/22
Paulsen Gisela Chief Operating Offi.. Chief Operating Officer Mar 15 Buy 1.198 16,500 19,767 16,500 03/17/22
ANDREWS RONALD ASBURY Chief Executive Offi.. Chief Executive Officer Mar 15 Buy 1.283 50,000 64,150 293,212 03/17/22
Redmond Cavan M. Director Director Mar 16 Buy 1.189 40,000 47,560 110,863 03/16/22
- - - Jan 22 Buy 1.71 1,460,280 2,497,079 16,176,484 01/22/21
KINGSLEY ALFRED D Director Director Dec 28 Option 1.34 66,508 89,121 384,111 12/28/20
KINGSLEY ALFRED D Director Director Dec 28 Sell 2.55 900 2,295 318,840 12/28/20
KINGSLEY ALFRED D Director Director Dec 23 Option 1.34 58,492 78,379 326,155 12/23/20
KINGSLEY ALFRED D Director Director Dec 23 Sell 2.54 5,148 13,076 315,639 12/23/20